Insmed
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
700 Us Highway 202/206, Bridgewater, New...Phone Number
(908) 977-9900Website
www.insmed.comRevenue
$819.6 MillionStock Symbol
INSMIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
1
1
About Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.Explore more
Insmed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Insmed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Insmed has new funding data
Earning: See what the market has to say on Insmed recently announced quarterly report
Insmed, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Insmed is spiking on competitors!
Click to see if Insmed had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Insmed
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Insmed launches new products
Check if Insmed has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Insmed as Masked Content
Find 3 more new buyers
Compare Similar Companies to Insmed
Compare insights from companies similar to Insmed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$3.2B
1K - 5K
Public
$54M
1996
ML
Marc LorberSenior Vice President and Chief Medical Officer, Lung Biotechnology, PBC
Company Profile Activity
Activity Insights
Insmed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Insmed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Insmed.
Insmed financials insights
Gather financial insights about Insmed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$775M
Insmed Tech Stack
A closer look at the technologies used by Insmed
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Earnings, Finance
Person-Based
Earnings, Finance
Open Position
Project
Clinical Operations
Insmed News & Media
Insmed Q2 Earnings Call Highlights
Insmed (NASDAQ:INSM) reported second-quarter 2026 revenue growth driven by the continued launch of BRINSUPRI and steady sales of ARIKAYCE, while raising its full-year BRINSUPRI revenue outlook and increasing its long-term peak-sales estimates for its leading products. BRINSUPRI generated $309.2 milInsmed Incorporated (INSM) Q2 2026 Earnings Call Transcript
Insmed Incorporated (INSM) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsBryan Dunn - Vice President of Investor RelationsWilliam...Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
—Total Company Revenues of $425.5 Million for the Second Quarter of 2026— —BRINSUPRI® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026— —ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $116.3...Here’s Why Baron Health Care Fund Remains Bullish on Insmed (INSM)
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Insmed
Sign Up For FreeTo access detailed company insights
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients... Read More
